Workflow
应收账款坏账准备
icon
Search documents
麒盛科技: 天健会计师事务所(特殊普通合伙)关于麒盛科技股份有限公司2024年年度报告信息披露监管问询函的专项说明
Zheng Quan Zhi Xing· 2025-06-19 13:17
Group 1 - The company received a non-standard audit opinion with an emphasis on the risk of loss related to accounts receivable from Shanghai Shufude Digital Technology Co., Ltd, amounting to 94.79 million yuan, with a bad debt provision of 66.79 million yuan for accounts receivable and 20.26 million yuan for other receivables [1][2] - Shanghai Shufude was recognized as a related party due to its significant reliance on the company's credit support and high sales on credit, leading to an additional recognition of 80.81 million yuan in related transactions for 2024 [1][2] - The company plans to purchase raw materials worth 25 million yuan and sell products worth 160 million yuan to Shanghai Shufude in 2025, indicating a growth in transaction scale [1] Group 2 - The company is required to disclose the equity structure and historical evolution of Shanghai Shufude, including any potential undisclosed related relationships or interests involving the controlling shareholders [2][3] - The independent audit and board of directors are tasked with reviewing the necessity and reasonableness of the large-scale related transactions planned for 2025, given the uncertainties surrounding the recovery of previous receivables [2][8] Group 3 - The sales model of Shanghai Shufude includes both direct sales and distribution, with a focus on order-based delivery, ensuring no inventory is held except for display samples [13][14] - The company has established a centralized system for order processing, where sales data is uploaded to facilitate procurement and delivery, ensuring credit checks are performed before shipment [12][13] - The pricing strategy for products sold to Shanghai Shufude is aligned with historical data from the company's domestic subsidiaries, ensuring consistency in pricing across channels [18][22] Group 4 - The company reported significant sales figures for smart beds and mattresses, with 2024 sales reaching 73.49 million yuan and 2025 sales in the first four months at 28.74 million yuan [16][24] - The accounts receivable from Shanghai Shufude as of 2024 amounted to 94.79 million yuan, reflecting the company's credit policy of allowing 90 days for payment after invoicing [24][25] - The company has implemented a sales policy that prohibits distributors from stockpiling products, ensuring fair pricing and market stability [15][22]
鲁抗医药: 和信会计师事务所(特殊普通合伙)关于山东鲁抗医药股份有限公司向特定对象发行股票申请文件的审核问询函的回复
Zheng Quan Zhi Xing· 2025-06-17 13:25
Core Viewpoint - The report discusses the financial performance and operational changes of Shandong Lukang Pharmaceutical Co., Ltd., highlighting significant growth in sales net profit margin and the impact of asset disposal on profitability [1][11]. Financial Performance - The company's operating revenue for the reporting periods was 562.14 million yuan, 614.67 million yuan, and 623.31 million yuan, with net profits of 13.80 million yuan, 24.62 million yuan, and 40.83 million yuan respectively [1][2]. - The sales net profit margins increased from 2.55% in 2022 to 4.18% in 2023, and further to 6.55% in 2024, primarily due to changes in product structure and asset disposal gains [3][11]. Gross Margin Analysis - The comprehensive gross margins for the reporting periods were 22.19%, 24.65%, and 23.96%, with the main business gross margin contributing significantly to overall profitability [3][4]. - The gross margin for the human medicine segment showed a steady increase, with the formulation drug gross margin rising from 33.68% to 41.46% over the reporting periods [4][5]. Cost Structure - The operating costs for the company were 473.95 million yuan, 463.13 million yuan, and 437.40 million yuan, indicating a controlled cost structure relative to revenue growth [2][6]. - Direct material costs accounted for approximately 75.45% of total revenue, reflecting the significant impact of raw material prices on overall profitability [6][8]. Market Competition and Product Performance - The raw material drug gross margin fluctuated, showing a decline in 2023 due to market competition, followed by a recovery in 2024 [5][9]. - The veterinary medicine segment experienced variable gross margins, influenced by market demand and competition, with margins of 15.66%, 18.16%, and 13.23% over the reporting periods [9][10]. Asset Disposal Impact - The company realized substantial asset disposal gains in 2024, amounting to 283.26 million yuan, significantly boosting net profit and sales net profit margin [9][10]. - The asset disposal was linked to the completion of land storage for the southern plant area, which was part of a strategic relocation initiative [10][11]. Export and Revenue Matching - The customs declaration data matched closely with overseas revenue, with minor discrepancies deemed reasonable due to small sample exports and timing differences [13][14]. - The company’s overseas revenue was diversified across several countries, including the UK, Netherlands, and Egypt, with stable trade and tariff policies [16][17]. Sales Expenses - The sales expense ratios were 8.45%, 9.40%, and 9.11%, significantly lower than the industry average, indicating efficient cost management in sales promotion [19][20]. - The increase in promotional expenses from 2023 was attributed to strategic marketing efforts to enhance product visibility and market share [19].
*ST开元: 关于深圳证券交易所《关于对开元教育科技集团股份有限公司的年报问询函》回复的公告
Zheng Quan Zhi Xing· 2025-06-06 14:12
Core Viewpoint - The company, Kaiyuan Education Technology Group, has responded to the Shenzhen Stock Exchange's inquiry regarding its annual report, highlighting significant changes in revenue across its business segments, particularly in educational training and intermediary services. Group 1: Educational Intermediary Business - The educational intermediary business generated revenue of 0.17 billion yuan, a year-on-year increase of 6.99%, while costs rose by 43.15% to 0.1 billion yuan [1][6] - The increase in revenue is attributed to the self-study business, despite a decline in average transaction amounts and student numbers compared to the previous year [5][6] - The company faces potential refund risks due to its revenue recognition method, which considers historical refund rates when accounting for income [5][11] Group 2: Educational Training Business - The educational training business reported revenue of 1.17 billion yuan, a significant decrease of 52.85% year-on-year, primarily due to the completion of prior year contracts and a decline in student numbers [1][9] - The average price per student and the number of students enrolled in training courses have also decreased, contributing to the revenue drop [8][9] - Refund policies for both online and offline courses are in place, with specific conditions under which refunds can be requested [10][11] Group 3: Franchise Business - The number of franchise campuses and their revenue contributions have declined, attributed to financial constraints affecting promotional activities and operational management [13] - The company has seen a reduction in the number of franchise campuses, impacting overall revenue from this segment [13][14] - The revenue recognition policy for franchise income is based on net collections from campuses, which have also decreased [12][13] Group 4: Book Sales Business - The book sales business has a low gross margin, influenced by procurement costs and sales strategies [16] - The company engages in both retail and wholesale book sales, with revenue recognized upon customer confirmation of receipt [15][16] - The sales model includes a mix of purchased and self-published educational materials, with a focus on maintaining control over inventory and sales processes [15][16]
至正股份: 深圳至正高分子材料股份有限公司备考合并审阅报告(上会师报字(2025)第9918号)
Zheng Quan Zhi Xing· 2025-05-29 15:12
客户H 深圳至正高分子材料股份有限公司 (除特别说明外,货币单位均为人民币元) 客户I之子公司i 3,709,482.32 3 , 7 0 9 ,4 8 2 . 3 2 100.00% 预 计无法 收回 其他 860,560.80 860,560.80 100.00% 预 计无法收 回 合 计 13,175,022.56 13,175,022.56 按组 合 计 提 坏 账 准 备 : 组合 计 提 项 目: 按信 用风 险特 征 组 合 计 提 坏 账 准 备 的应 收 账 款 名 称 应收 账款 坏账 准 备 预期 信 用 损失 率 按信用风险特征组合计 提坏账准备的应收账款 合 计 6 1 1 , 9 60 , 4 6 8 . 3 0 2 , 21 5 , 9 76. 5 8 0. 36% (3) 报 告期 计 提 、 收 回或 转 回 的坏 账 准 备情 况 项 且 2 0 2 4 . 12 . 3 1 本期计 提 5 9 5, 3 2 3 . 0 0 本期核 销 520,819.91 本期收回或转 回 786,696.72 外币报表折算差 异 171,755.00 ( 4) 报 告 期 实 际核 销 ...
和达科技: 和达科技2024年度业绩快报暨业绩预告更正公告
Zheng Quan Zhi Xing· 2025-03-30 08:52
Core Viewpoint - Zhejiang Heda Technology Co., Ltd. has revised its 2024 annual performance forecast and performance report, indicating significant changes in financial data, which have not yet been audited by an accounting firm [1][4]. Financial Data Summary - The revised total operating revenue is 479.3735 million yuan, a decrease of 6.8357 million yuan compared to the previous forecast, representing a decline of 1.41% [3]. - The revised operating profit is -17.5483 million yuan, a reduction of 14.0325 million yuan from the previous forecast, reflecting a decrease of 399.13% [3]. - The revised total profit is -17.6079 million yuan, down by 14.0325 million yuan from the previous forecast, indicating a decrease of 392.47% [3]. - The revised net profit attributable to the parent company is -5.6360 million yuan, a decrease from the previous forecast [3]. - The revised net profit attributable to the parent company after deducting non-recurring gains and losses is -14.3851 million yuan, a reduction of 10.7429 million yuan, showing a decrease of 294.96% [3]. - The revised basic earnings per share is -0.05 yuan, a decrease of 0.10 yuan from the previous forecast, representing a decline of 200% [3]. Reasons for Revision - The revision is based on a prudent assessment of the recoverability of accounts receivable, leading to an increase in the provision for bad debts and a corresponding reduction in operating revenue, operating profit, total profit, and net profit attributable to the parent company [3]. - The company has communicated thoroughly with the annual audit firm regarding this revision, confirming that there are no significant disagreements [4]. Other Notes - The company expresses apologies for any inconvenience caused to investors due to this revision and emphasizes the importance of prudent judgment and communication with the audit firm in future financial reporting [4].
金宏气体: 金宏气体:审计报告
Zheng Quan Zhi Xing· 2025-03-25 11:35
Core Opinion - The audit report for Jinhong Gas Co., Ltd. indicates that the financial statements for the year ending December 31, 2024, fairly represent the company's financial position and operating results in accordance with accounting standards [3]. Financial Statements - The audit covered various financial statements including the consolidated balance sheet, income statement, cash flow statement, and changes in equity for both consolidated and parent company [1][3]. - The consolidated revenue for 2024 was reported at 2,525,277,683.91 yuan [4][5]. Key Audit Matters - **Accounts Receivable Provision**: As of December 31, 2024, the accounts receivable balance was 402,012,847.36 yuan, with a provision for bad debts of 22,225,193.12 yuan. The management's judgment on the recoverability of accounts receivable was identified as a key audit matter [3][4]. - **Revenue Recognition**: The recognition of revenue is significant for the financial statements and is subject to inherent risks of manipulation. The revenue recognition process was also deemed a key audit matter [4][5]. - **Goodwill Impairment**: The goodwill balance was reported at 334,402,411.11 yuan, with an impairment provision of 36,684,534.17 yuan. The assessment of goodwill impairment involves significant management judgment and was recognized as a key audit matter [6][7]. Management Responsibilities - The management is responsible for preparing the financial statements in accordance with accounting standards and ensuring that internal controls are in place to prevent material misstatements due to fraud or error [9][10]. Auditor Responsibilities - The auditor's goal is to obtain reasonable assurance that the financial statements are free from material misstatement, whether due to fraud or error, and to issue an audit opinion based on the audit evidence obtained [10][11].
播恩集团:中汇会计师事务所(特殊普通合伙)关于公司首次公开发行股票的财务报表及审计报告
2023-02-13 16:01
4-1-1 | | 页 次 | | --- | --- | | 、审计报告 | 1-6 | | 、财务报表 | 7-22 | | (一) 合并资产负债表 | 7-8 | | (二) 合并利润表 | 9 | | (三) 合并现金流量表 | 10 | | (四) 合并所有者权益变动表 | 11-14 | | (五) 母公司资产负债表 | 15-16 | | (六) 母公司利润表 | 17 | | (七) 母公司现金流量表 | 18 | | (八) 母公司所有者权益变动表 | 19-22 | 4-1-2 审计报告 中汇会审[2022]6968号 播恩集团股份有限公司全体股东: 一、审计意见 我们审计了播恩集团股份有限公司(以下简称播恩集团)财务报表,包括2019 年12月31日、2020年12月31日、2021年12月31日、2022年6月30日的合并及母公司 资产负债表,2019年度、2020年度、2021年度、2022年1-6月的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及财务报表附 注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了播恩集团2 ...